KiOmedine® brings unique clinical value in high impact pathologies and major social burdens

Invalidating OsteoArthritis
KioMedinevsone is the first soft implant intended to treating OsteoArthritis, an invalidating pathology that affects more than 100 millions of patients worldwide.

The unique character of KiOmedine® resides in its innovative chemical design and non-animal origin that allow developing safe medical devices to offer high clinical efficacy thanks to tunable attributes such as lubrication and combating free-radical species.

Skin Aging
Thanks to free radical scavenging, KiOmedine®-based dermal fillers provide tunable tissues filling properties with unique skin protection and hydration while stimulating collagen synthesis.

Dry Eye Disease
Thanks to its unique hydrating and lubricating properties, as well as its ability to protect tissues against oxidative stress, KiOmedine® is a component of choice in eyedrops formulations or for more innovative treatments of the posterior segment.

From years of research to commercial stage

Through a series of comparative, pre-clinical and clinical studies, KiOmed Pharma repeatedly demonstrated that its exclusive technology KiOmedine® CM-Chitosan offers unique and sustainable attributes in comparison with competitive products. Our multidisciplinary team experts continually strive to advance innovative solutions to address unmet needs in the treatment of invalidating OsteoArthritis symptoms, dry eye disease and skin aging pathologies.

KiOmed Pharma Downloads

KioMedine - Model vs One - Unique Soft Implant for OsteoArthritis Treatment Brochure

Contact supplier